2011
Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy
Misra D, Xie W, Regan M, Ross R, Lee G, Germain D, Kantoff P, Oh W. Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU International 2011, 108: 1086-1091. PMID: 21410629, DOI: 10.1111/j.1464-410x.2010.10037.x.Peer-Reviewed Original ResearchConceptsAR CAG repeat lengthAndrogen deprivation therapyTime to progressionAR-CAGProstate-specific antigenProstate cancerDeprivation therapyOverall survivalAndrogen receptorProstate cancer treated with androgen deprivation therapyEfficacy of androgen deprivation therapyResponse to ADTCorrelated to time to progressionMetastatic prostate cancerRepeat lengthTertiary care institutionCAG repeat polymorphismCAG repeat lengthGleason scoreMetastatic diseaseClinical stageBorderline significancePatientsProstateAndrogen
2010
Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy
Sun T, Lee G, Werner L, Pomerantz M, Oh W, Kantoff P, Freedman M. Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 1871-1878. PMID: 20615892, PMCID: PMC3755451, DOI: 10.1158/1055-9965.epi-10-0216.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyResponse to ADTAssociated with prostate cancer aggressivenessProstate cancer aggressivenessDeprivation therapyESR2 geneCancer aggressivenessEfficacy of androgen deprivation therapyResponse to androgen deprivation therapySex steroid hormone receptorsAssociated with disease aggressivenessD'Amico risk classificationNormal prostate growthAggressive prostate cancerProstate cancer casesProstate cancer developmentTagging single nucleotide polymorphismsHospital-based cohortInherited variationSteroid hormone receptorsClinically relevant traitsProstate growthProstate cancerPathological stageDisease aggressiveness
2008
Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer
Ross R, Oh W, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin M, Regan M, Kantoff P, Freedman M. Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal Of Clinical Oncology 2008, 26: 842-847. PMID: 18281655, DOI: 10.1200/jco.2007.13.6804.Peer-Reviewed Original ResearchConceptsEfficacy of androgen deprivation therapyAndrogen deprivation therapyTime to progressionProstate cancerAdvanced prostate cancers treated with androgen deprivation therapyProstate cancer treated with androgen deprivation therapyResponse to ADTAssociated with time to progressionImproved time to progressionInfluence of inherited variationAdvanced prostate cancerEffective systemic therapyResponse to therapyAndrogen metabolic pathwaysGermline genetic variationDNA polymorphismsAndrogen deprivationAndrogen axisGenetic variationSystemic therapyGenotype patientsAndrogen pathwayClinical benefitAndrogen metabolismInherited variationEfficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer
Ross R, Xie W, Regan M, Pomerantz M, Nakabayashi M, Daskivich T, Sartor O, Taplin M, Kantoff P, Oh W. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer. Cancer 2008, 112: 1247-1253. PMID: 18293426, DOI: 10.1002/cncr.23304.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAndrogen AntagonistsCohort StudiesDisease ProgressionFollow-Up StudiesGonadotropin-Releasing HormoneHumansMaleMiddle AgedNeoplasm StagingNeoplasms, Hormone-DependentOrchiectomyProstate-Specific AntigenProstatectomyProstatic NeoplasmsRetrospective StudiesSurvival RateConceptsEfficacy of androgen deprivation therapyAndrogen deprivation therapy initiationAndrogen deprivation therapyProstate-specific antigenHormone-sensitive prostate cancerProstate cancerGleason scoreDeprivation therapyM+ patientsLower serum prostate-specific antigenUse of androgen deprivation therapyCohort of prostate cancer patientsLower biopsy Gleason scoreSerum prostate-specific antigenMetastatic disease statusBiopsy Gleason scoreAdvanced prostate cancerAbsence of metastasesProstate cancer patientsShortened TTPMedian TTPLocal therapyDecreased TTPM patientsRetrospective study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply